# CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma

> **NCT04812691** · PHASE1 · COMPLETED · sponsor: **Shanghai Ming Ju Biotechnology Co., Ltd.** · enrollment: 12 (actual)

## Conditions studied

- Diffuse Large B Cell Lymphoma

## Interventions

- **BIOLOGICAL:** JWCAR029 (CD19-targeted Chimeric Antigen Receptor Cells)

## Key facts

- **NCT ID:** NCT04812691
- **Lead sponsor:** Shanghai Ming Ju Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-10
- **Primary completion:** 2021-06-30
- **Final completion:** 2023-04-25
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2023-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04812691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04812691, "CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04812691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*